Iridex is a worldwide leader in developing and manufacturing innovative and versatile laser-based medical systems and delivery devices to treat glaucoma and retinal diseases, as well as ENT disorders. The company maintains a deep commitment to the success of its customers, offering comprehensive technical, clinical, and service support programs. Iridex's products are sold in the United States and Germany through a direct sales force and in over 100 countries through more than 70 independent distributors. The company is headquartered in Mountain View, California, and was founded in 1989.
Iridex's mission is to improve patient outcomes through cutting-edge laser technology and exceptional customer support. The company's innovative approach has positioned it as a leader in the medical device industry, particularly in the treatment of eye and ear disorders.
With a strong focus on research and development, Iridex continuously invests in new technologies to enhance its product offerings and expand its market reach. The company's commitment to quality and innovation has earned it a reputation as a trusted partner in the medical community.
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
| Ownership Public Company |
| Stock IRIX (Nasdaq) |
B2B professionals would contact Iridex for its innovative laser-based medical systems and delivery devices, which are essential for treating glaucoma, retinal diseases, and ENT disorders. The company's comprehensive support programs and global distribution network make it an attractive partner for medical device sales and service.
Sales teams selling medical devices, particularly those focused on ophthalmology and ENT, should reach out to Iridex. Recruiters seeking roles in medical device innovation and distribution should also consider Iridex. Partners offering complementary services in the medical technology sector can explore opportunities with Iridex.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Iridex